BriaCell To Host Virtual Key Opinion Leader Event On Bria-IMT Potential In Advanced Metastatic Breast Cancer On October 26, 2023 Featuring Dr. Adam M. Brufsky From University Of Pittsburgh School Of Medicine And Dr. Saranya Chumsri From Mayo Clinic
Portfolio Pulse from Benzinga Newsdesk
BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW) (TSX:BCT) will host a virtual Key Opinion Leader (KOL) event on October 26, 2023, to discuss the potential of Bria-IMT™ in advanced metastatic breast cancer. The event will feature Dr. Adam M. Brufsky from the University of Pittsburgh School of Medicine and Dr. Saranya Chumsri from Mayo Clinic. BriaCell recently reported patient survival and clinical benefit with median overall survival of 13.5 months in BriaCell's advanced metastatic breast cancer patients. Bria-IMT™ has been awarded Fast Track status by the U.S Food and Drug Administration for the treatment of advanced metastatic breast cancer and initiated a phase 3 pivotal registration study.
October 11, 2023 | 1:11 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BriaCell's upcoming KOL event and recent positive clinical data for Bria-IMT™ could potentially boost investor confidence and have a positive impact on the company's stock.
The announcement of the KOL event and the positive clinical data for Bria-IMT™ could potentially increase investor interest in BriaCell, leading to a potential increase in the company's stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
BriaCell's upcoming KOL event and recent positive clinical data for Bria-IMT™ could potentially boost investor confidence and have a positive impact on the company's stock.
The announcement of the KOL event and the positive clinical data for Bria-IMT™ could potentially increase investor interest in BriaCell, leading to a potential increase in the company's stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
BriaCell's upcoming KOL event and recent positive clinical data for Bria-IMT™ could potentially boost investor confidence and have a positive impact on the company's stock.
The announcement of the KOL event and the positive clinical data for Bria-IMT™ could potentially increase investor interest in BriaCell, leading to a potential increase in the company's stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100